Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ning Leng

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Plos Genetics|June 21, 2013
The gene desert mammary carcinoma susceptibility locus Mcs1a regulates Nr2f1 modifying mammary epithelial cell differentiation and proliferationBart M G Smits, Jill D Haag, Anna I Rissman, et al.
Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.
Nature Communications|June 26, 2021
Molecular determinants of response to PD-L1 blockade across tumor typesRomain Banchereau, Ning Leng, Oliver Zill, et al.
European Urology|March 8, 2021
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical TrialThomas Powles, Michael B Atkins, Bernard Escudier, et al.
Lancet (London, England)|December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.
Plos Genetics|December 10, 2016
The Transcription Factor Nfatc2 Regulates β-Cell Proliferation and Genes Associated with Type 2 Diabetes in Mouse and Human IsletsMark P Keller, Pradyut K Paul, Mary E Rabaglia, et al.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Nature Medicine|February 6, 2021
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Cell Reports. Medicine|January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyMahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Plos Genetics|June 21, 2013
The gene desert mammary carcinoma susceptibility locus Mcs1a regulates Nr2f1 modifying mammary epithelial cell differentiation and proliferationBart M G Smits, Jill D Haag, Anna I Rissman, et al.
Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.
Nature Communications|June 26, 2021
Molecular determinants of response to PD-L1 blockade across tumor typesRomain Banchereau, Ning Leng, Oliver Zill, et al.
European Urology|March 8, 2021
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical TrialThomas Powles, Michael B Atkins, Bernard Escudier, et al.
Lancet (London, England)|December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.
Plos Genetics|December 10, 2016
The Transcription Factor Nfatc2 Regulates β-Cell Proliferation and Genes Associated with Type 2 Diabetes in Mouse and Human IsletsMark P Keller, Pradyut K Paul, Mary E Rabaglia, et al.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Nature Medicine|February 6, 2021
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Cell Reports. Medicine|January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyMahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
Pageof 4